NCT06561048: An ongoing trial by Corvus Pharmaceuticals, Inc.
This trial is ongoing. It must report results 2 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06561048 |
|---|---|
| Title | A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 2, 2024 |
| Completion date | Nov. 30, 2026 |
| Required reporting date | Nov. 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 25, 2025 |
| Days late | None |